Other Information
−Removed: During the period from January 1, 2025 to March 31, 2025, our executive officers and/or directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
+Added: During the period from April 1, 2025 to June 30, 2025, our officers (as defined in Rule 16a-1(f) under the Exchange Act) and/or directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
Name and Title Action Date Trading Arrangement Total Shares Authorized
1 unchanged sentence
Rule 10b5-1* Non-Rule 10b5-1**
−Removed: Kevin Gorman, Ph.D.
+Added: 96,400 2/4/2026
+Added: Chief Executive Officer
+Added: Matthew Abernethy
5/23/2025 X 77,176 2/28/2026
−Removed: Kevin Gorman, Ph.D.
−Removed: Adoption 2/24/2025 X 115,935 2/04/2026
+Added: Chief Financial Officer
+Added: Darin Lippoldt
+Added: 6/9/2025 X 122,989 2/28/2027
+Added: Chief Legal Officer
______________
16 unchanged sentences
Incorporated by reference to the Company’s Registration Statement on Form S-1 (Registration No.
−Removed: Form of Stock Option Grant Notice and Option Agreement for grants made on or after Ja nuary 30 , 202 5 made under the Neurocrine Biosciences, Inc.
+Added: Neurocrine Biosciences, Inc.
2025 Equity Incentive Plan
+Added: Incorporated by reference to Exhibit 99.2 of the Company’s Registration Statement on Form S-8 (Registration No.
+Added: Form of Standard Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc.
+Added: 2025 Equity Incentive Plan
+Added: Incorporated by reference to Exhibit 99.3 of the Company’s Registration Statement on Form S-8 (Registration No.
+Added: Form of Standard Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc.
+Added: 2025 Equity Incentive Plan
+Added: Incorporated by reference to Exhibit 99.4 of the Company’s Registration Statement on Form S-8 (Registration No.
+Added: Form of Director Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc.
+Added: 2025 Equity Incentive Plan
+Added: Incorporated by reference to Exhibit 99.5 of the Company’s Registration Statement on Form S-8 (Registration No.
+Added: Form of Director Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc.
+Added: 2025 Equity Incentive Plan
+Added: Incorporated by reference to Exhibit 99.6 of the Company’s Registration Statement on Form S-8 (Registration No.
+Added: Form of Non-U.S.
+Added: Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc.
+Added: 2025 Equity Incentive Plan
+Added: Incorporated by reference to Exhibit 99.7 of the Company’s Registration Statement on Form S-8 (Registration No.
+Added: Form of Non-U.S.
+Added: Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc.
+Added: 2025 Equity Incentive Plan
+Added: Incorporated by reference to Exhibit 99.8 of the Company’s Registration Statement on Form S-8 (Registration No.
+Added: Amended and Restated Employment Agreement dated May 30, 2025 between the Company and Eiry W.
+Added: Roberts, M.D.
+Added: Incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed on May 30, 2025
Neurocrine Biosciences, Inc.
−Removed: Executive Severance Plan effective February 7 , 2025
−Removed: Incorporated by reference to Exhibit 10.26 of the Company’s Annual Report on Form 10-K filed on February 10, 2025
−Removed: Amended and Restated Employment Agreement effective February 7 , 2025 between the Company and Kyle W.
−Removed: Incorporated by reference to Exhibit 10.31 of the Company’s Annual Report on Form 10-K filed on February 10, 2025
−Removed: Amended and Restated Employment Agreement effective February 7 , 2025 between the Company and Matthew C.
−Removed: Incorporated by reference to Exhibit 10.32 of the Company’s Annual Report on Form 10-K filed on February 10, 2025
−Removed: Amended and Restated Employment Agreement effective February 7, 2025 between the Company and Eric Benevich
−Removed: Incorporated by reference to Exhibit 10.33 of the Company’s Annual Report on Form 10-K filed on February 10, 2025
−Removed: Amended and Restated Employment Agreement effective February 7, 2025 between the Company and Jude Onyia
−Removed: Incorporated by reference to Exhibit 10.34 of the Company’s Annual Report on Form 10-K filed on February 10, 2025
−Removed: Amended and Restated Employment Agreement effective February 7, 2025 between the Company and Eiry W.
−Removed: Incorporated by reference to Exhibit 10.35 of the Company’s Annual Report on Form 10-K filed on February 10, 2025
−Removed: Amended and Restated Exclusive License Agreement dated January 24, 2025 by and between Takeda Pharmaceutical Company Limited and the Company
+Added: 2018 Employee Stock Purchase Plan, as amended and restated
+Added: Incorporated by reference to Exhibit 99.1 of the Company’s Registration Statement on Form S-8 (Registration No.
31.1 Description:
2 unchanged sentences
Certification of Chief Financial Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934
+Added: 32* Description:
Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.
16 unchanged sentences
______________
−Removed: + Management contract or compensatory arrangement.
−Removed: * Certain information in this exhibit has been omitted pursuant to Item 601 of Regulation S-K.
+Added: + Management contract or compensatory plan or arrangement.
* These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C.
3 unchanged sentences
NEUROCRINE BIOSCIENCES, INC.
+Added: July 30, 2025
/s/ Matthew C.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.